BioCryst Pharmaceuticals (BCRX) Short Interest Ratio & Short Volume

Short interest is the volume of BioCryst Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 23,080,000 shares of BCRX short. 11.59% of BioCryst Pharmaceuticals' shares are currently sold short. Learn More on BioCryst Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCRX shares currently have a short interest ratio of 5.0. Learn More on BioCryst Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioCryst Pharmaceuticals: Jane Street Group LLC, Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.59% of BioCryst Pharmaceuticals' floating shares are currently sold short.

BioCryst Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 23,080,000 shares, a decline of 3.9% from the previous total of 24,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

11.59% of BioCryst Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to BioCryst Pharmaceuticals: Repligen Co. (6.38%), Halozyme Therapeutics, Inc. (9.08%), Madrigal Pharmaceuticals, Inc. (23.81%), Ionis Pharmaceuticals, Inc. (9.16%), Alkermes plc (6.70%), Ligand Pharmaceuticals Incorporated (6.41%), Amicus Therapeutics, Inc. (6.94%), Innoviva, Inc. (15.56%), Celldex Therapeutics, Inc. (12.34%), Dynavax Technologies Co. (13.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks.

Short selling BCRX is an investing strategy that aims to generate trading profit from BioCryst Pharmaceuticals as its price is falling. BCRX shares are trading down $0.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for BioCryst Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BCRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCRX, twice per month. The most recent reporting period available is June, 15 2025.